# Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

> **NCT01689259** · PHASE1 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Adults

## Interventions

- **DRUG:** SL TNX-102 at 2.4 mg
- **DRUG:** SL TNX-102 at 4.8 mg
- **DRUG:** SL TNX-102-A at 2.4 mg
- **DRUG:** Cyclobenzaprine tablets

## Key facts

- **NCT ID:** NCT01689259
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-12
- **Final completion:** 2014-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01689259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01689259, "Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01689259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*